晚期与标准全身[68Ga]Ga-PSMA-11 PET/CT在生化复发前列腺癌中临床表现的比较
研究纳入2021年1月至2024年4月在上海仁济医院接受标准与晚期长轴视野[68Ga]Ga-PSMA-11 PET/CT的127例根治性前列腺切除术后生化复发患者,比较两种显像的PET阳性率及对治疗决策的影响。晚期显像(利尿后)PET阳性率80.31%(102/127)显著高于标准显像65.35%(83/127)(P < 0.001),14.17%(18/127)患者因晚期显像改变了治疗方案。
要点
- 晚期长轴视野[68Ga]Ga-PSMA-11 PET/CT利尿后图像质量均满足临床诊断要求。
- 晚期显像PET阳性率80.31%(102/127)显著高于标准显像65.35%(83/127),P < 0.001。
- 14.17%(18/127)患者因晚期显像检测优势改变了治疗方案。
核心结论
- 利尿后晚期长轴视野[68Ga]Ga-PSMA-11 PET/CT较标准显像的PET阳性率凸显其作为生化复发前列腺癌有价值诊断工具的潜力。
- 本研究为利尿后晚期长轴视野[68Ga]Ga-PSMA-11 PET/CT用于日常临床前列腺癌显像铺平道路,有助于更准确和及时的诊断。
研究设计与样本
- 2021年1月至2024年4月在上海仁济医院入组127例根治性前列腺切除术后生化复发前列腺癌患者,均接受标准与晚期长轴视野[68Ga]Ga-PSMA-11 PET/CT。
- 比较两种显像在患者层面及不同解剖区域的PET阳性率,评估晚期显像的附加诊断价值及对治疗计划的改变。
主要发现
- 所有患者利尿后晚期长轴视野[68Ga]Ga-PSMA-11 PET/CT图像质量均满足临床诊断要求。
- 晚期显像PET阳性率80.31%(102/127)显著高于标准显像65.35%(83/127),P < 0.001。
- 晚期显像病灶SUVmax为16.69 ± 16.42,高于标准显像的11.91 ± 10.72,P < 0.001。
- 晚期显像TBR为6.26 ± 7.21,高于标准显像的3.44 ± 3.57,P < 0.001。
- 14.17%(18/127)患者因晚期显像较标准显像的检测优势而改变治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Enhanced lesion detection in prostate cancer is observed with late [68 Ga]Ga-PSMA-11 PET/CT imaging compared to standard [68 Ga]Ga-PSMA-11 PET/CT imaging (50-100 min p.i.). However, the poor image quality of late imaging using short axial field of view (SAFOV) PET/CT has hindered its sole clinical adoption. Conversely, the image quality of late imaging with a long axial field of view (LAFOV) [68 Ga]Ga-PSMA-11 PET/CT fulfills clinical diagnostic requirements. Nonetheless, the diagnostic efficacy of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis and its impact on treatment decisions, compared to standard LAFOV [68 Ga]Ga-PSMA-11 PET/CT, remains unclear. This study aims to compare the rate of PET positivity between late and standard LAFOV [68 Ga]Ga-PSMA-11 PET/CT and to evaluate the influence of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis on treatment decisions relative to standard scans. METHODS: From January 2021 to April 2024, 127 patients with biochemical recurrence of prostate cancer post-radical prostatectomy were enrolled to undergo both standard and late LAFOV [68 Ga]Ga-PSMA-11 PET/CT scans at Shanghai Renji Hospital. We compared the rate of PET positivity between the two modalities at the patient level and across different anatomical regions. We assessed the added diagnostic value of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT and its impact on modifying patient treatment plans. RESULTS: The image quality of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis in all patients met clinical diagnostic requirements. The rate of PET positivity of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis were significantly higher than those of standard LAFOV [68 Ga]Ga-PSMA-11 PET/CT (80.31% [102/127] vs. 65.35% [83/127]; P < 0.001). Late LAFOV [68 Ga]Ga-PSMA-11 PET/CT demonstrated higher lesion SUVmax (16.69 ± 16.42 vs. 11.91 ± 10.72, P < 0.001) and TBR (6.26 ± 7.21 vs. 3.44 ± 3.57, P < 0.001) compared to standard LAFOV scans. Additionally, 14.17% (18/127) of patients experienced changes in their treatment regimen due to the superior detection capabilities of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis compared to the standard scan. CONCLUSIONS: The rate of PET positivity of late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis compared to standard LAFOV [68 Ga]Ga-PSMA-11 PET/CT highlight its potential as a valuable diagnostic tool for biochemically recurrent prostate cancer. This study paves the way for using late LAFOV [68 Ga]Ga-PSMA-11 PET/CT with forced diuresis for prostate cancer imaging in daily clinical practice, facilitating more accurate and timely diagnoses.
引用
- Chen Q, Dong L, Xu L, et al. Comparison of clinical performance between late and standard total-body [68 Ga]Ga-PSMA-11 in biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 39540904. doi:10.1007/s00259-024-06980-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。